

SUPPLEMENTARY APPENDIX

Aryl-hydrocarbon receptor repressor gene in primary graft dysfunction after lung transplantation

Michaela R. Anderson MD MS, Ethan A. Edwin MS, Joshua M. Diamond MD MS,
Anthony Ferrante Jr MD PhD, Joshua Sonett MD,
Frank D'Ovidio MD, Selim Arcasoy MD, Edward Cantu III MD,
Jason D. Christie MD MS, David J. Lederer MD MS

Table E1: Characteristics of subjects with reperfusion adipose samples

	No PGD (n=15)	PGD (n=4)
Age	56 (26-69)	62 (51-70)
Sex, male	11 (73)	4 (100)
Body mass index, kg/m ²	25.8 (19.3-31.6)	25.0 (19.9-30.2)
Diagnosis		
Obstructive Lung Disease	4 (27)	0 (0)
Cystic Fibrosis	4 (27)	0 (0)
Interstitial Lung Disease	7 (47)	4 (100)
LAS at transplant	38.0 (31.0-94.1)	43.4 (30.3-95.0)
Donor smoking history	2 (13)	0 (0)
Pre-operative corticosteroids	9 (60)	4 (100)
MV at Transplant	0 (0)	0 (0)
ECMO before Transplant	0 (0)	1 (25)
Intra-operative ECMO/CPB	6 (40)	2 (50)
Total Ischemic Time, minutes	321 (179-483)	317 (201-480)
Type of Transplant, double	8 (53)	1 (25)

Values presented as N (%) or median (range)

Definition of abbreviations: PGD: primary graft dysfunction; LAS: lung allocation score; MV: mechanical ventilation; ECMO: extracorporeal membrane oxygenation; CPB: cardiopulmonary bypass